Ponatinib Tablets (Iclusig): Key Facts And Dosage
Comprehensive guide to ponatinib (Iclusig) for treating resistant CML and Ph+ ALL in adults.
Ponatinib, sold under the brand name Iclusig, is a tyrosine kinase inhibitor used to treat adults with specific types of leukaemia, including chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL).
About ponatinib tablets
Ponatinib hydrochloride is the active ingredient in Iclusig tablets. It belongs to a class of medications known as tyrosine kinase inhibitors (TKIs). In CML and Ph+ ALL, a genetic abnormality produces the BCR-ABL enzyme, which drives uncontrolled white blood cell production. Ponatinib specifically targets and blocks BCR-ABL, including the resistant T315I mutation, halting leukaemia cell growth and spread.
Available as film-coated tablets in strengths of 10 mg, 15 mg, 30 mg, and 45 mg, the tablets are oval or round, white to off-white, biconvex, and debossed with identifiers like ‘NZ’ for 10 mg or ‘A5’ for 15 mg. Swallow tablets whole with or without food, ideally at the same time daily. Do not cut, crush, or dissolve them.
Key facts about ponatinib tablets
- Dosage form: Film-coated oral tablets (10 mg, 15 mg, 30 mg, 45 mg).
- Starting dose: Typically 45 mg once daily for CML monotherapy; 30 mg once daily for newly diagnosed Ph+ ALL with chemotherapy.
- Administration: Once daily, with or without food; continue until disease progression or unacceptable toxicity.
- Monitoring: Regular blood tests, cardiovascular assessments, and response evaluations per guidelines.
- Storage: Room temperature, away from moisture and heat.
When is ponatinib used?
Iclusig is indicated for adult patients with:
- Chronic phase (CP), accelerated phase (AP), or blast phase (BP) CML resistant or intolerant to dasatinib or nilotinib, or with T315I mutation.
- Ph+ ALL resistant or intolerant to prior TKI therapy.
- Newly diagnosed Ph+ ALL in combination with chemotherapy.
Treatment requires specialist oversight due to serious risks like arterial occlusive events (AOEs). Assess cardiovascular status before starting and optimize risk factors.
How does ponatinib work?
Ponatinib inhibits BCR-ABL tyrosine kinase, abnormal in Ph+ leukaemias due to the Philadelphia chromosome (t(9;22) translocation). It is potent against native and mutated BCR-ABL, including T315I, which resists other TKIs like imatinib, dasatinib, and nilotinib. By blocking this enzyme, ponatinib prevents leukaemia cell proliferation, induces apoptosis, and achieves responses in resistant cases.
Dosage and how to take ponatinib
The recommended starting dose is 45 mg orally once daily for CP-CML, AP-CML, BP-CML, and Ph+ ALL monotherapy. For newly diagnosed Ph+ ALL with chemotherapy, start at 30 mg once daily, reducing to 15 mg upon MRD-negative complete remission.
Dose adjustments for toxicity:
| Event | First Occurrence | Second Occurrence | Third Occurrence |
|---|---|---|---|
| CP-CML | 30 mg once daily | 15 mg once daily | 10 mg once daily |
| AP-CML, BP-CML, Ph+ ALL Monotherapy | 30 mg once daily | 15 mg once daily | Discontinue or 10 mg |
| Newly Diagnosed Ph+ ALL | 15 mg once daily | 15 mg once daily | 10 mg once daily |
Reduce to 15 mg for CP-CML patients achieving molecular response (MR2). Discontinue if no complete hematologic response by 3 months. For hepatic impairment, reduce dose by 50% initially.
Monitor response per guidelines; interrupt for severe adverse events like AOEs, then resume at reduced dose based on recovery.
Getting the most from ponatinib tablets
- Take exactly as prescribed; do not adjust without consulting your doctor.
- Report symptoms like chest pain, vision changes, or swelling immediately.
- Avoid strong CYP3A inhibitors (e.g., ketoconazole); dose adjustments may be needed.
- Maintain heart-healthy lifestyle: control blood pressure, cholesterol, and avoid smoking.
- Attend all monitoring visits for blood tests, ECGs, and eye exams.
- For diarrhoea, use lactaid if lactose intolerant; manage constipation with fluids and fibre.
Side effects of ponatinib tablets
Ponatinib carries boxed warnings for AOEs, venous thromboembolic events (VTEs), heart failure, and hepatotoxicity. AOEs occurred in 26% of PACE trial patients (15% serious), including myocardial infarction and stroke, even in younger patients.
Common side effects (>20%):
- Hypertension (up to 34% in PhALLCON), rash, dry skin, abdominal pain, fatigue, headache, nausea, constipation, arthralgia.
- Grade 3/4 lab abnormalities: thrombocytopenia, neutropenia, leukopenia.
Serious risks:
- AOEs: Stroke, MI, peripheral artery disease (dose-related; monitor vision, pulses).
- VTEs: 6% in PACE, including retinal vein occlusion.
- Heart failure: 9% incidence; fatal cases reported.
- Hepatotoxicity: Monitor liver enzymes; interrupt if elevated.
- Other: PRES, neuropathy, ocular toxicity, fluid retention, pancreatitis, haemorrhage.
Report severe symptoms urgently. In trials, 20-48% discontinued due to adverse events.
How to cope with ponatinib side effects
Hypertension: Monitor BP regularly; use antihypertensives as prescribed.
Rash/Dry skin: Moisturize, avoid irritants; topical steroids if needed.
Diarrhoea: Stay hydrated; anti-diarrhoeals like loperamide; consider lactaid.
Fatigue: Pace activities, ensure rest and nutrition.
Fluid retention: Elevate limbs, low-salt diet; diuretics if advised.
For serious events like AOEs or PRES (seizures, headache, vision loss), interrupt therapy and seek emergency care.
Precautions and warnings
- Cardiovascular: Baseline and ongoing ECG, echo; optimize risks pre-treatment.
- Hepatitis B: Screen and monitor; antiviral prophylaxis if positive.
- Pregnancy: Contraindicated (Category D); use effective contraception.
- Driving: May cause dizziness; caution until effects known.
- Interactions: CYP3A inhibitors/inducers, St. John’s wort.
Interactions of ponatinib
Avoid strong CYP3A inhibitors (reduce dose by 50%); monitor with inducers. No major food interactions, but consistency aids absorption.
Important information about all medicines
Never share ponatinib. Inform doctors/dentists of use before procedures. Keep out of reach of children.
FAQ
Who should not take ponatinib?
Patients with uncontrolled hypertension, recent arterial/venous thrombosis, or decompensated heart failure. Use caution in hepatic impairment.
How long is ponatinib taken?
Until disease progression, unacceptable toxicity, or complete response per guidelines (e.g., discontinue if no hematologic response by 3 months).
Does ponatinib cure leukaemia?
No, it controls disease in resistant cases but is not curative; responses vary.
Can ponatinib cause blood clots?
Yes, AOEs in 20-48%, VTEs in 6%; monitor closely.
What if I miss a dose?
Take as soon as remembered unless near next dose; do not double.[10]
References
- Iclusig EPAR – Product Information — European Medicines Agency (EMA). 2023. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf
- ICLUSIG (ponatinib) Tablets Prescribing Information — U.S. Food and Drug Administration (FDA). 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203469s038lbl.pdf
- Iclusig | European Medicines Agency — EMA. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig
- Iclusig Tablets — NPS MedicineWise. 2023. https://www.nps.org.au/medicine-finder/iclusig-tablets
- Iclusig Prescribing Information — Iclusig.com. 2023. https://www.iclusig.com/sites/default/files/2023-02/iclusig-prescribing-information.pdf
- Ponatinib tablets – Iclusig — Patient.info. 2023. https://patient.info/medicine/ponatinib-tablets-iclusig
Similar Articles
Read full bio of medha deb
